Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innovive Parmaceuticals, New York-based biopharmaceutical company, has enrolled its first patients in a phase I clinical trial of its investigational cancer vaccine Inno-105 in adult patients with advanced solid malignancies.
Subscribe to our email newsletter
The objectives of the trial are to determine safety, dose, pharmacokinetic profile and preliminary efficacy of Inno-105. The treatment is derived from a naturally occurring peptide that inhibits cell growth and division by interacting with OGFr, a unique receptor found on the nuclear membrane of a wide range of malignant cells.
Preclinical studies have demonstrated antitumor activity in numerous tumor types. In addition, Inno-105 has recently demonstrated antitumor activity in a phase I pancreatic cancer study conducted at The Hershey Medical Center, the original licensor for the drug. The new phase I study will attempt to further increase the administered dose of Inno-105 and will expose the drug to a wider range of tumor types.
Inno-105 is the first drug in the company’s portfolio. Over the next year Innovive said it plans to expand its pipeline with additional clinical stage compounds.